NCT00357669 - Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Unverricht-Lundborg Disease

Interventions

DRUG

Brivaracetam 25 mg

"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"

DRUG

Brivaracetam 50 mg

"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"

OTHER

Placebo

"* Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use"

Trial Locations (13)

Kuopio

Tampere

Marseille

Montpellier

Bologna

Messina

Milan

Napoli

Heemstede

Heeze

Saint Pierre Cedex

Gothenburg

Tunis

All Listed Sponsors

lead

UCB Pharma SA

INDUSTRY